Table 1.
Characteristics of the MM patients at baseline and association with sFLCR (n = 180).
Table 2.
Correlation analysis between clinical parameters of the disease and sFLCR, sFLC kappa and sFLC lambda levels.
Fig 1.
(A) Overall Survival (OS) and (B) Progression-free survival (PFS) of all MM patients (n = 180) stratified according to a low (<47) or high (≥47) sFLCR.
Table 3.
Univariate and multivariate analysis of prognostic factors for Overall Survival (OS) and Progression-free Survival (PFS) in patients with newly diagnosed MM (n = 180).
Table 4.
Prognostic value obtained with different sFLC cut-offs.
Fig 2.
Prognostic value of sFLCR regarding the treatment scheme (A) Overall Survival (OS) of patients under treatment with novel agents (n = 69) stratified by sFLCR. (B) Overall Survival (OS) of patients under treatment with traditional agents (n = 63) stratified by sFLCR.
Fig 3.
A) Overall Survival (OS) of all patients based on International Staging System (ISS) (n = 180). B) OS of patients in ISS-1 stratified by sFLCR (n = 56). C) OS of patients in ISS-2 stratified by sFLCR (n = 65). D) OS of patients in ISS-3 stratified by sFLCR (n = 59).
Table 5.
Prognostic value of International Staging System (ISS) and stratified by sFLCR.
Fig 4.
A) Progression-free survival (PFS) of all patients based on International Staging System (ISS) (n = 180). B) PFS of patients in ISS-1 stratified by sFLCR (n = 56). C) PFS of patients in ISS-2 stratified by sFLCR (n = 65). D) PFS of patients in ISS-3 stratified by sFLCR (n = 59).
Fig 5.
(A) Overall Survival (OS) and (B) Progression-Free Survival (PFS) of all patients based on New Staging System (NSS) (n = 180).
Table 6.
Prognostic value of “New Staging System (NSS)” based on sFLCR and B2M for Overall Survival (OS) and Progression-Free Survival (PFS).
Table 7.
Comparison of the prognostic ability of the International Staging System (ISS) and New Staging System (NSS) using the Akaike Information Criterion (AIC) values.
Fig 6.
(A) Disease Free Survival (DFS) of the patients achieving Complete Response (CR) (n = 19) and stringent CR (sCR) (n = 17). (B) Overall Survival (OS) of the patients achieving Complete Response (CR) (n = 19) and stringent CR (sCR) (n = 17).